TCRT Stock Financial Analysis - Alaunos Therapeutics, Inc. (NasdaqCM) Stock

Overview

Alaunos Therapeutics, Inc., based in the United States, operates primarily within the biotechnology sector, focusing on the development of personalized oncology therapies. The company’s key initiative revolves around its T-cell receptor (TCR) therapy platform, which targets various cancers by harnessing and enhancing the body's immune response to recognize and eliminate cancer cells specifically and effectively. Alaunos is particularly notable for its pioneering research in TCR therapies against solid tumors, aiming to address the significant unmet medical needs in this challenging area of cancer treatment. Their approach combines cutting-edge genetic sequencing and modification techniques to tailor treatments to the individual genetic profile of a patient’s tumor, thereby enhancing the precision and effectiveness of cancer therapies.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Alaunos Therapeutics, Inc. as of June 30, 2025 is 0.01 MM.
The operating income for Alaunos Therapeutics, Inc. as of June 30, 2025 is -4.04 MM.
The net income for Alaunos Therapeutics, Inc. as of June 30, 2025 is -3.99 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	0.01	-4.04	-3.99
2025-03-31	0.01	-4.16	-4.07
2024-12-31	0.01	-4.81	-4.68
2024-09-30	0.01	-7.42	-11.78
2024-06-30	0.01	-13.50	-19.13
2024-03-31	0.01	-20.56	-26.77
2023-12-31	0.01	-28.49	-35.14
2023-09-30	0.01	-31.15	-36.46
2023-06-30	2.93	-32.18	-36.83
2023-03-31	2.92	-33.33	-37.99
2022-12-31	2.92	-32.74	-37.73
2022-09-30	2.91	-36.87	-40.37
2022-06-30	0.40	-47.40	-54.25
2022-03-31	0.40	-60.67	-66.98
2021-12-31	0.40	-73.15	-78.75
2021-09-30	0.40	-85.77	-89.73
2021-06-30		-87.30	-87.31
2021-03-31		-83.26	-83.24
2020-12-31		-80.36	-79.98
2020-09-30		-73.62	-72.95
2020-06-30
2020-03-31

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31
2024-09-30	-7.36	-7.39
2024-06-30	-11.95	-11.98
2024-03-31	-1.67	-1.68
2023-12-31	-2.20	-2.20
2023-09-30	-23.20	-23.62
2023-06-30	-24.07	-24.35
2023-03-31	-2.55	-2.56
2022-12-31	-2.61	-2.61
2022-09-30	-2.82	-2.77
2022-06-30	-3.79	-3.71
2022-03-31	-4.68	-4.68
2021-12-31	-5.51
2021-09-30	-6.29	-6.29
2021-06-30	-6.13	-6.19
2021-03-31	-5.86	-5.86
2020-12-31	-5.72
2020-09-30	-5.44	-5.42
2020-06-30	-9.96	-9.94
2020-03-31	-10.35	-10.33

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Alaunos Therapeutics, Inc. as of June 30, 2025 is -2.85 MM.
The cash from financing activities for Alaunos Therapeutics, Inc. as of June 30, 2025 is 3.26 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-2.85		3.26
2025-03-31	-3.83
2024-12-31	-4.97
2024-09-30	-11.76	1.50	0.00
2024-06-30	-17.36	1.50	0.00
2024-03-31	-22.68	1.37	-11.98
2023-12-31	-30.14	1.35	-18.14
2023-09-30	-29.89	-0.25	-9.66
2023-06-30	-29.66	-0.27	-11.77
2023-03-31	-30.84	-0.19	0.21
2022-12-31	-29.23	-0.19	6.37
2022-09-30	-37.23	-0.46	-2.29
2022-06-30	-40.66	-0.81	24.74
2022-03-31	-53.92	-2.63	24.76
2021-12-31	-61.47	-3.32	25.78
2021-09-30	-63.38	-6.73	26.36
2021-06-30	-69.87	-8.37	1.46
2021-03-31	-62.42	-9.98	1.46
2020-12-31	-57.01	-9.78	102.12
2020-09-30	-51.59	-6.11	104.75
2020-06-30
2020-03-31

Valuation Metrics : PE, PriceToBook, PriceToTBV

The p/book for Alaunos Therapeutics, Inc. as of June 30, 2025 is 7.34.
The p/tbv for Alaunos Therapeutics, Inc. as of June 30, 2025 is 7.34.

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30		7.34	7.34
2025-03-31	-0.20	0.86	0.86
2024-12-31		1.28	1.28
2024-09-30	-0.26	1.32	1.32
2024-06-30	-0.43	2.40	2.40
2024-03-31	-0.82	2.14	2.14
2023-12-31	-0.47	1.22	1.22
2023-09-30	-0.86	1.46	1.46
2023-06-30	-3.22	4.14	4.14
2023-03-31	-3.92	3.83
2022-12-31		4.86	4.86
2022-09-30		9.20	9.20
2022-06-30	-3.99	5.44	5.44
2022-03-31	-1.77	2.39	2.39
2021-12-31	-1.88	2.55	2.55
2021-09-30	-1.65	2.16	2.16
2021-06-30	-1.70	1.68	1.68
2021-03-31	-1.78	1.40	1.40
2020-12-31	-1.84	1.02	1.02
2020-09-30	-2.01	1.01	1.01
2020-06-30	-1.16	0.90	0.90
2020-03-31	-1.20	0.81	0.81

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

The ebit/ev for Alaunos Therapeutics, Inc. as of June 30, 2025 is -0.55.
The ebit (3y)/ev for Alaunos Therapeutics, Inc. as of June 30, 2025 is -2.69.

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30	-0.55	-2.69
2025-03-31	-17.99	-38.96
2024-12-31	-6.57	-15.75
2024-09-30	-7.55	-12.63
2024-06-30	-3.63	-5.95
2024-03-31	-2.04	-2.86
2023-12-31	-7.24	-11.02
2023-09-30	-2.77	-4.47
2023-06-30	-0.35	-0.55
2023-03-31	-0.30	-0.50
2022-12-31	-0.28	-0.47
2022-09-30	-0.16	-0.22
2022-06-30	-0.30	-0.42
2022-03-31	-0.90	-1.09
2021-12-31	-0.82	-0.96
2021-09-30	-1.11	-1.15
2021-06-30	-1.23	-1.25
2021-03-31	-1.74	-1.79
2020-12-31	-2.46	-2.58
2020-09-30	-6.42	-7.08
2020-06-30	19.20	11.82
2020-03-31	5.07	3.14

Management Effectiveness

The roa for Alaunos Therapeutics, Inc. as of June 30, 2025 is -0.87.
The roe for Alaunos Therapeutics, Inc. as of June 30, 2025 is -1.08.
The roic for Alaunos Therapeutics, Inc. as of June 30, 2025 is -3.85.
The croic for Alaunos Therapeutics, Inc. as of June 30, 2025 is -3.62.
The ocroic for Alaunos Therapeutics, Inc. as of June 30, 2025 is -3.62.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-0.87	-1.08	-3.85	-3.62	-3.62
2025-03-31	-1.95	-2.46	-4.32	-3.77	-4.32
2024-12-31	-1.43	-1.87	-4.32	-3.77	-4.32
2024-09-30	-0.98	-1.38	-5.07	-4.20	-4.60
2024-06-30	-0.55	-0.91	-5.58	-6.94	-4.73
2024-03-31	-0.56	-0.95	-2.42	-2.64	-1.98
2023-12-31	-0.54	-1.14	-2.42	-2.64	-1.98
2023-09-30	-0.50	-0.92	-1.59	-1.80	-1.28
2023-06-30	-0.51	-0.95	-1.08	-1.22	-0.87
2023-03-31	-0.44	-0.77	-0.78	-0.63	-0.63
2022-12-31	-0.35	-0.59	-0.65	-0.64	-0.60
2022-09-30	-0.48	-0.79	-0.68	-0.67	-0.63
2022-06-30	-0.63	-0.76	-0.80	-0.25	-0.60
2022-03-31	-0.61	-0.75	-0.86	-0.41	-0.69
2021-12-31	-0.54	-0.54	-0.90	-0.45	-0.70
2021-09-30	-0.54	-0.62	-0.91	-0.44	-0.64
2021-06-30	-0.48	-0.53	-0.93	-0.82	-0.74
2021-03-31	-0.42	-0.46	-0.75	-0.64	-0.57
2020-12-31	-0.73	-0.84	-0.53	0.24	-0.38
2020-09-30	-0.62	-0.69	-0.49	0.32	-0.35
2020-06-30	-1.73	-2.04	-0.77	0.66	-0.28
2020-03-31	-1.47	-1.65	-0.67	0.65	-0.22

Gross Margins

The gross margin for Alaunos Therapeutics, Inc. as of June 30, 2025 is -31.09.
The net margin for Alaunos Therapeutics, Inc. as of June 30, 2025 is -370.00.
The operating margin for Alaunos Therapeutics, Inc. as of June 30, 2025 is -378.36.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	-31.09	-370.00	-378.36
2025-03-31	-196.29	-1,682.86	-1,059.57
2024-12-31	-196.29	-1,682.86	-1,059.57
2024-09-30	-698.43	-2,732.71	-1,928.86
2024-06-30	-1,649.17	-4,462.33	-3,427.17
2024-03-31	-1,229.20	-2,430.40	-2,076.93
2023-12-31	-1,229.20	-2,430.40	-2,076.93
2023-09-30	-6.75	-12.59	-11.00
2023-06-30	-6.66	-12.59	-11.00
2023-03-31	-6.71	-13.00	-11.40
2022-12-31	-6.86	-13.87	-13.92
2022-09-30	-85.07	-13.87	-13.92
2022-06-30	-104.24	-136.30	-128.29
2022-03-31	-123.73	-168.30	-161.64
2021-12-31	-123.73	-197.87	-192.99
2021-09-30	-138.19	-225.45	-221.04
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31